Articles  |   June 2016
SEE Question
Article Information
Cardiovascular Anesthesia / Critical Care / Education / CPD / Neuromuscular Diseases and Drugs / Obstetric Anesthesia / Patient Safety / Pharmacology / Respiratory System / Articles
Articles   |   June 2016
SEE Question
ASA Monitor 06 2016, Vol.80, 34-35.
ASA Monitor 06 2016, Vol.80, 34-35.
A recent report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States (MHAUS) analyzed outcomes from malignant hyperthermia (MH) episodes over a recent six-year period (2007-12) compared to a previous cohort (1987-2006). According to this report, which of the following statements is most likely true?
MH is a well-studied disease with a specific antidote. ASA temperature monitoring standards require temperature monitoring “for every patient receiving anesthesia … when clinically significant changes in body temperature are intended, anticipated or suspected.” Given the increase in preparedness and understanding of MH over the past several years, it could be expected that the risk of dying from the disorder would be decreasing. A recent report from the MHAUS North American Malignant Hyperthermia Registry reviewed MH events. The MH event reports were analyzed to update rates of cardiac arrest and death due to MH. Investigators also tested the hypothesis that the risk of dying from an MH episode is increased in patients with inadequate temperature monitoring.
First Page Preview
First page PDF preview
First page PDF preview ×
View Large
Submit a Comment
Submit A Comment

Contributors must reveal any conflict of interest. Comments are moderated.

Affiliation & Institution
I have a potential conflict of interest
Comment Title

This feature is available to Subscribers Only
ASA Member Login or Create an Account ×